Key facts
- This page summarizes BIOGEN INC.'s Form 4 filing for SANGAMO THERAPEUTICS, INC (SGMO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 28 Sep 2023, 17:30.
BIOGEN INC. - 26 Sep 2023 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- SGMO
- Reported as of
- 26 Sep 2023
- Net transaction value
- -$3,000,000
- SEC form
- 4
- Accepted by SEC
- 28 Sep 2023, 17:30:09 UTC
- Prior SEC filing
- 07 Aug 2023
- Next SEC filing
- 06 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- BIOGEN INC. By: /s/ Michael Dambach, Vice President and Treasurer
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
BIOGEN INC. filed Form 4 for SANGAMO THERAPEUTICS, INC (SGMO) on 28 Sep 2023.
Change
- Previous filing in this sequence was filed on 07 Aug 2023.
- Current net transaction value: -$3,000,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SGMO
transaction
Common Stock
Sale
- Transaction value
- $3,000,000
- Shares
- -6,000,000
- Change %
- -25%
- Price
- $0.5000
- Shares after
- 17,652,466
- Date
- 26 Sep 2023
- Ownership
- By Biogen MA Inc.
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
BIOGEN INC. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.